Kiora Pharmaceuticals (KPRX) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medicus Pharma (MDCX) has outperformed Kiora Pharmaceuticals (KPRX) over the past year, losing 46.7% versus a loss of 61.5%. Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPRX | MDCX |
|---|---|---|
| Share price | $0.7202 | $1.14 |
| Market cap | $3.19M | $3.16M |
| 1-day change | -12.28% | -2.16% |
| YTD return | -63.44% | -25.82% |
| 1-year return | -61.49% | -46.71% |
| 5-year return | -99.87% | — |
| EPS (TTM) | $-2.72 | $-76.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-10.84M | $-47.28M |
| 52-week high | $2.91 | $114.00 |
| 52-week low | $0.72 | $1.06 |
| Distance from 52-week high | -75.25% | -99.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +1566.20% | +296.48% |
| Average volume | 35.23K | 116.55K |
| Shares outstanding | 4.42M | 2.79M |
| Employees | 13 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDCX has outperformed KPRX by 14.8 percentage points over the past year.
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
KPRX vs MDCX FAQ
Which is bigger, Kiora Pharmaceuticals or Medicus Pharma?
Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $3.16M for Medicus Pharma (MDCX).
Which stock has performed better over the past year, KPRX or MDCX?
MDCX returned -46.71% over the past 12 months, compared with -61.49% for KPRX (price return, excluding dividends). Past performance does not predict future results.
Are Kiora Pharmaceuticals and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.